companies coherus-biosciences-inc 
LexBlog IP
JUNE 22, 2023
On June 16, 2023, Coherus BioSciences, Inc. and Surface Oncology, Inc. Coherus’ Chairman and Chief Executive Officer said that “[t]his transaction is well-timed, as it coincides with the accelerating growth of our biosimilar revenues driven by the launch of CIMERLI and near-term launch of YUSIMRY.
LexBlog IP
DECEMBER 28, 2023
Coya Announces Agreement with Dr. Reddy’s Laboratories for Treatment of Neurodegenerative Diseases In March, Coya Therapeutics, Inc. (“Coya”), a biopharmaceutical company based in Houston, announced a worldwide agreement with Dr. Reddy’s Laboratories Ltd. (“Dr.
LexBlog IP
SEPTEMBER 16, 2021
If approved, Coherus Biosciences, Inc. will commercialize FYB201 (also known as CHS-201) in the United States according to the terms of a November 2019 license and development agreement between Coherus and Bioeq.
Expert insights. Personalized for you.
52 
Let's personalize your content